IMMX
Immix Biopharma, Inc.Healthcare·Biotechnology
$9.00
$490M market cap
Revenue
$0.0M
Free Cash Flow
$-21.1M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's d
2-Year Price History
$8.78+332.5%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -10.7 | -10.8 | -10.1 | -9.8 | -9.9 | -0.0 | 90.6 | 1.0 | 38.3 | -200.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -10.8 | -10.9 | -10.7 | -11.0 | -11.2 | -0.2 | 100.4 | 1.1 | 38.3 | -138.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$9.00
Market Cap$490M
Enterprise Value$400M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-4.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-20.8M
Free Cash Flow$-21.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-169.1%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.0M
Days to Cover4.4
Change (vs Prior)+1.9%
Need at least 2 settlement dates for chart
Employees
Headcount18
Revenue / Employee$0
Gross Profit / Employee$-7,265
Cash Runway
51.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
45.0%(+44.4% YoY)
66 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.5%(+6.1% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
1.1%(+1.1% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $43.7M | $5.94 | +$8.0M | +$43.7M | +1.2% | $209.29B |
| Saturn V Capital Management LP | $33.6M | $5.96 | +$6.3M | +$33.6M | +1.4% | $552M |
| EVENTIDE ASSET MANAGEMENT, LLC | $23.2M | $5.23 | +$0 | +$23.2M | -1.6% | $5.96B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $16.3M | $9.11 | +$16.3M | +$16.3M | — | $4.04T |
| MILLENNIUM MANAGEMENT LLC | $15.9M | $5.39 | +$824K | +$15.9M | -0.5% | $127.40B |
| MARSHALL WACE, LLP | $15.0M | $5.14 | −$3.1M | +$15.0M | +0.6% | $92.71B |
| Logos Global Management LP | $11.2M | $5.94 | +$2.0M | +$11.2M | -1.6% | $1.94B |
| Bleichroeder LP | $9.1M | $3.39 | +$0 | +$1.4M | -2.9% | $579M |
| FRANKLIN RESOURCES INC | $8.8M | $5.23 | −$103K | +$8.8M | -0.2% | $403.03B |
| Velan Capital Investment Management LP | $6.7M | $8.78 | +$6.4M | +$6.7M | -5.3% | $160M |
| Blue Owl Capital Holdings LP | $5.0M | $5.23 | −$4.0M | +$5.0M | -2.3% | $372M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $4.3M | $5.19 | +$706K | +$3.8M | -0.6% | $77.14B |
| BlackRock, Inc.Passive | $4.3M | $7.70 | +$3.1M | +$4.2M | -0.2% | $5.69T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $4.2M | $5.90 | +$2.0M | +$2.8M | +2.3% | $1.61T |
| LGT Fund Management Co Ltd. | $3.8M | $7.95 | +$2.7M | +$3.8M | -0.1% | $2.30B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $3.8M | $9.11 | +$3.8M | +$3.8M | -0.2% | $864.93B |
| GREAT POINT PARTNERS LLC | $3.2M | $9.11 | +$3.2M | +$3.2M | -4.5% | $408M |
| Institute for Wealth Management, LLC. | $3.1M | $9.11 | +$3.1M | +$3.1M | +0.5% | $931M |
| Burkehill Global Management, LP | $2.7M | $5.23 | +$0 | +$2.7M | +5.0% | $1.91B |
| VANGUARD FIDUCIARY TRUST COPassive | $2.3M | $9.11 | +$2.3M | +$2.3M | — | $395.83B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
+0.07%
avg per quarter
Holders (ex-self)
+0.02%
excl. this stock
Buyers (this Q)
-0.08%
52 buyers · $0.12B in
Sellers (this Q)
+0.12%
13 sellers · $-0.01B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+11.3%
how holders react when this stock falls
On quiet Qs
+40.3%
−10% to +10% baseline
On rallies (+10%+)
+14.7%
how they react when this stock rises
Holders' portfolio flow this Q
-0.4%
outflows — trims may be forced
Sellers' portfolio flow this Q
-3.2%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-7.3%
Holder mid (any stock)
-5.2%
Holder rally (any stock)
-7.6%
Biggest decreases this quarter
ADAGE CAPITAL PARTNERS GP, L.L.C.exited−$7.8MBlue Owl Capital Holdings LP−$4.0Mα-2.3MARSHALL WACE, LLP−$3.1Mα+0.6AMERIPRISE FINANCIAL INCexited−$2.4MPERCEPTIVE ADVISORS LLCexited−$1.8MRENAISSANCE TECHNOLOGIES LLCexited−$1.4MLongaeva Partners L.P.exited−$513KJump Financial, LLCexited−$177KPersistent Asset Partners Ltdexited−$166KQuadrature Capital Ltdexited−$116K
New buyers this quarter
Top-5 holders · 53.8%
JANUS HENDERSON GROUP PLC--
Saturn V Capital Management LP--
EVENTIDE ASSET MANAGEMENT, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
MILLENNIUM MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
JANUS HENDERSON GROUP PLC4.8MSaturn V Capital Management LP3.7MEVENTIDE ASSET MANAGEMENT, LLC2.5MMILLENNIUM MANAGEMENT LLC1.8MMARSHALL WACE, LLP1.6MLogos Global Management LP1.2MBleichroeder LP1.0MFRANKLIN RESOURCES INC969KADAGE CAPITAL PARTNERS GP, L.L.C.—Velan Capital Investment Management LP740K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$15.006670.0%
Last Year (3 analysts)$13.675190.0%
Current Price$9.00
Analyst Ratings
4
Buy: 4Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$30K
6 txns · 2 insiders · 11,019 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | BUY | Morris Gabriel S | director, officer: CFO | 770 | $6.58 | $5K | $1.92M |
| 2025-12-10 | BUY | Rachman Ilya M | director, officer: CEO and Chairman | 746 | $6.67 | $5K | $7.62M |
| 2025-09-17 | BUY | Rachman Ilya M | director, officer: CEO and Chairman | 2,500 | $2.02 | $5K | $2.30M |
| 2025-09-16 | BUY | Morris Gabriel S | director, officer: CFO | 2,600 | $1.97 | $5K | $573K |
| 2025-06-18 | BUY | Morris Gabriel S | director, officer: CFO | 2,225 | $2.28 | $5K | $656K |
| 2025-06-18 | BUY | Rachman Ilya M | director, officer: CEO and Chairman | 2,178 | $2.29 | $5K | $2.61M |
Order Flow (FINRA, ~3w lag)
37.9%retail+5.4pp
14.3%dark-1.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
IMMIX BIOPHARMA: The High-Cost Service Company Masquerading as a Biotech
Overall Risk
8/10
Fraud
4/10
Dilution
9/10
Insolvency
7/10
Earnings Overstated
3/10
Hidden Liabilities
8/10
Legal
4/10
Audit Warnings
5/10
Hidden Upside
3/10
Contextually Acceptable
3/10